Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03911453
Recruitment Status : Recruiting
First Posted : April 11, 2019
Last Update Posted : February 17, 2021
Sponsor:
Information provided by (Responsible Party):
University of Arizona

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : November 30, 2021